Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC …
S Elgohary, RA Eissa, HM El Tayebi - International Journal of Molecular …, 2023 - mdpi.com
Breast cancer (BC) is not only a mass of malignant cells but also a systemic inflammatory
disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and …
disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and …
Thymoquinone Inhibition of Chemokines in TNF-α-Induced Inflammatory and Metastatic Effects in Triple-Negative Breast Cancer Cells
The lack of identifiable molecular targets or biomarkers hinders the development of
treatment options in triple-negative breast cancer (TNBC). However, natural products offer a …
treatment options in triple-negative breast cancer (TNBC). However, natural products offer a …
Downstream signaling of inflammasome pathway affects patients' outcome in the context of distinct molecular breast cancer subtypes
C Saponaro, A Fanizzi, M Sonnessa, P Mondelli… - Pharmaceuticals, 2022 - mdpi.com
Inflammasomes are protein complexes involved in the regulation of different biological
conditions. Over the past few years, the role of NLRP3 in different tumor types has gained …
conditions. Over the past few years, the role of NLRP3 in different tumor types has gained …
Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
G Adinew, SS Messeha, R Badisa, E Taka… - The FASEB …, 2022 - Wiley Online Library
Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a
metastatic nature. TNBC lacks the expression of the progesterone receptor, estrogen …
metastatic nature. TNBC lacks the expression of the progesterone receptor, estrogen …
The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production
CM Chang, TR Liang, HYP Lam - Biomolecules, 2024 - mdpi.com
Triple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer
subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and …
subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and …
IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2
Inflammatory breast cancer (IBC) is a highly metastatic and lethal breast cancer. As many as
25–30% of IBCs are triple negative (TN) and associated with low survival rates and poor …
25–30% of IBCs are triple negative (TN) and associated with low survival rates and poor …
Effect of diallyl trisulfide on TNF-α-induced CCL2/MCP-1 release in genetically different triple-negative breast cancer cells
KJW Kanga, P Mendonca, KFA Soliman… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Diallyl trisulfide (DATS) has been shown to prevent and inhibit breast
carcinogenesis. CCL2/MCP-1 has been shown to play a significant role in breast cancer …
carcinogenesis. CCL2/MCP-1 has been shown to play a significant role in breast cancer …
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan
Y Wang, X Zhang, X Xie, W Chen, M Li… - Cancer biology & …, 2020 - Taylor & Francis
Breast cancer is the most common malignant tumor in women. Its incidence is associated
with obesity and metabolic syndrome (MetS), which are highly prevalent world widely and …
with obesity and metabolic syndrome (MetS), which are highly prevalent world widely and …
Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
X Li, L Tang, Q Chen, X Cheng, Y Liu… - Chinese Medical …, 2022 - mednexus.org
Background: Cancer immunotherapy has emerged as a promising strategy against triple-
negative breast cancer (TNBC). One of the immunosuppressive pathways involves …
negative breast cancer (TNBC). One of the immunosuppressive pathways involves …
Thymoquinone enhances paclitaxel anti-breast cancer activity via inhibiting tumor-associated stem cells despite apparent mathematical antagonism
HA Bashmail, AA Alamoudi, A Noorwali, GA Hegazy… - Molecules, 2020 - mdpi.com
Thymoquinone (TQ) has shown substantial evidence for its anticancer effects. Using human
breast cancer cells, we evaluated the chemomodulatory effect of TQ on paclitaxel (PTX). TQ …
breast cancer cells, we evaluated the chemomodulatory effect of TQ on paclitaxel (PTX). TQ …